New hope for AF patients: needle-based stroke prevention without daily pills

NCT ID NCT07430956

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Feb 25, 2026 · Last updated May 29, 2026 · Updated 8 times

Summary

This study tests two experimental drugs (REGN7508 and REGN9933) to prevent strokes in about 2,600 people with atrial fibrillation (an irregular heartbeat) who cannot or choose not to take standard blood thinners. The drugs are designed to block a clotting factor to reduce stroke risk. Participants will receive either one of the drugs or a placebo, and researchers will monitor for strokes, bleeding events, and side effects over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

AA Medical Research Center (MRC)
RECRUITING

Flint, Michigan, 48504, United States
Cardiology Associates Medical Group
RECRUITING

Ventura, California, 93003, United States
K&R Research LLC
RECRUITING

Marion, Ohio, 43302, United States
Profound Research LLC at Southern California Heart Specialists
RECRUITING

Pasadena, California, 91105, United States
SEC Clinical Research
RECRUITING

Dothan, Alabama, 36305, United States

Conditions

Explore the condition pages connected to this study.

ATRIAL FIBRILLATION (AF)